Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder

Overactive Bladder Clinical Trial

Official title:

First in Human (FIH) Study for the Evaluation of the Safety and Early Performance of the Vibe Delivery System for the Delivery of Botox™ in Subjects With Idiopathic Overactive Bladder (OAB)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03874780
• Other study ID #: CL-100
• Status: Completed
• Phase: N/A
• Start date: January 29, 2019
• Est. completion date: March 31, 2019

Study information

• Verified date: March 2019
• Source: Vensica Medical Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This First In Human study is aimed to evaluate the safety and initial efficacy of the Vibe delivery system in delivering Botox (TM) to the bladder wall in patients diagnosed with overactive bladder.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: March 31, 2019
• Est. primary completion date: March 31, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Female subjects between the ages of 18 to 80 years old diagnosed with idiopathic OAB.

2. Subject has signed Informed Consent Form and is willing and able to comply with all requirements of the protocol.

3. Subjects with symptoms of incontinence associated with OAB for = 3 months prior to screening.

4. Subjects who are non-responsive, non-compliant or intolerable to pharmacologic oral therapy (e.g., anticholinergic agents).

5. Subject is willing and able to initiate self-catheterization post-treatment, if required.

6. Subjects with PVR =200 ml.

7. Subjects who are mentally competent, with the ability to understand and comply with the requirements of the study.

8. A negative urine pregnancy test during screening in women with childbearing potential. A female subject will also agree to use an adequate birth control method for the duration of her participation in the study and for a period of 6 months after participation completion.

Exclusion Criteria:

1. Subjects currently using Clean intermittent catheterization (CIC) or indwelling catheter to manage their urinary incontinence.

2. Pregnant or breastfeeding women, or women of childbearing potential who are planning to become pregnant during the study period or not practicing reliable contraception methods.

3. Subjects with clinically significant Bladder Outlet Obstruction (BOO) according to medical history.

4. Subjects with active urinary tract infection, as diagnosed on screening urinalysis.

5. Subjects with known polyuria or polydipsia.

6. Subjects with a known positive diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, or Amyotrophic Lateral Sclerosis.

7. Subjects with OAB due to any known neurological reason.

8. Subjects currently undergoing biofeedback, pelvic muscle rehabilitation, pelvic floor physical therapy, or electrical-stimulation who are unwilling to discontinue such treatments for the duration of study participation.

9. Subject with a 24-hour total urine volume voided greater than 3,000 ml, as measured at screening visit.

10. Predominance of stress incontinence in the opinion of the investigator, determined by medical history.

11. Subjects with vesico-ureteral reflux, genitourinary fistulae.

12. Subjects with pelvic organ prolapse stage III or IV, (i.e. the most distal part of the prolapse protruding more than 1 cm beyond the hymen at straining).

13. Subjects with prior Botox™ therapy of any serotype within 12 weeks for any indication, including urologic condition.

14. Subjects with a history of pelvic radiation therapy.

15. Subject who is morbidly obese (BMI > 40 Kg/m2).

16. Subjects with a history of treatment for two or more UTIs within 6 months prior to screening or use of prophylactic antibiotics to prevent chronic UTIs.

17. Subjects on immunomodulatory therapy (suppressive or stimulatory).

18. History or evidence of any pelvic or lower tract genitourinary abnormalities, malignancy, bladder surgery (excluding stress incontinence or pelvic organ prolapse surgeries), or disease, other than OAB.

19. Subjects with operative sling erosion.

20. History of interstitial cystitis/painful bladder syndrome, in the opinion of the investigator.

21. Subjects with current major psychiatric disorder or other psychiatric or medical issues that would interfere with study participation (e.g. dementia, psychosis, upcoming major surgery, etc).

22. Subject has severe cardiac, pulmonary, renal, or hepatic disease that in the judgment of the study physician would preclude participation in this study.

23. Any other condition or medical history, that to the discretion of the investigator and/or Sponsor, excludes the subject from participation in the study.

Related Conditions & MeSH terms

• Overactive Bladder
• Urinary Bladder, Overactive

Intervention

Device:
• Vibe Delivery system
delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system

Locations

Country	Name	City	State
Czechia	Jablonec Nad Nisou Medical Center	Jablonec Nad Nisou
Portugal	Braga Medical Center	Braga

Sponsors (1)

Lead Sponsor	Collaborator
Vensica Medical Ltd.

Countries where clinical trial is conducted

Czechia,  Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Treatment Response	Percentage of subjects who have a Positive Treatment Response on the Treatment Benefit Scale (TBS)	12 weeks
Other	Change in Quality of Life Total Score	Change from baseline in Overactive Bladder Quality of life (OAB-q) total score. The OAB-q questionnaire is a validated, multi-sectional questionnaire that assesses the patient's coping with overactive bladder symptoms. The questionnaire is commonly used in clinical research and clinical setting for this indication, and consists of the following 6 scores: Symptoms severity score; Coping score; Concern/worry score; Social score; Sleep score; Quality of life score These scores are further analyzed to obtain two domains: Quality of Life total score (improvement is demonstrated in higher scores), and Symptoms Bother Score (improvement is demonstrated in lower scores).	12 weeks
Primary	Serious Adverse Events Reporting	Incidence of device related SAEs	7 days
Secondary	Serious Adverse Events Reporting	Incidence of device related SAEs within	12 weeks
Secondary	Incontinence	Change from Baseline in the mean number of Episodes of Urinary Incontinence/24h, as assessed by urinary diary	12 weeks
Secondary	Micturition	Change from Baseline in frequency of Micturition Episodes/24h, as assessed by urinary diary	12 weeks
Secondary	Nocturia	Change from Baseline in Daily Average Number of Nocturia Episodes, as assessed by urinary diary	12 weeks
Secondary	Urgency	Change from baseline in Urinary urgency, as assessed by urinary diary	12 weeks